
NORPEN 2019

FINAL PROGRAM

The 12th annual NorPEN meeting
held at Moesgaard Museum in Aarhus, Denmark

13-15 November 2019



Theme: Phase IV Studies and Beyond

Hosted by: Department of Clinical Epidemiology at Aarhus University and Aarhus University Hospital

Contact: norpen2019@clin.au.dk

13 November	Pre-course: Topics in Phase IV Studies	
12.30-16.30	Part I “Estimation of prescription durations based on the parametric Waiting Time Distribution” Associate prof. Henrik Støvring, Aarhus University	William Scharff Auditorium, Aarhus University campus
14 November	Pre-course: Topics in Phase IV Studies	
9.00-10.50	Part II “Missing data” Prof. Irene Petersen, University College London & Aarhus University	Meeting room 301, Moesgaard Museum
14 November	Executive Committee meeting	
9.00-11.00	Executive Committee members only	Meeting room 302, Moesgaard Museum
14 November	12th NorPEN meeting - Moesgaard Museum Auditorium	
8.30-	Registration	
11.10-11.15	Welcome	Mette Nørgaard & Vera Ehrenstein
	Keynote presentations <i>Moderator: Mette Nørgaard</i>	
11.15-11.45	Message from regulator: Regulatory approval today and in the future? A shift in paradigm?	Nikolai Brun, Danish Medicines Agency
11.45-12.15	Post-marketing obligations in the EU, a regulatory science perspective on the performance of the system	Marie Louise De Bruin, Copenhagen Centre for Regulatory Science
12.15-12.45	Pharmacovigilance - a European regulatory perspective: a case of medication safety in pregnancy	Hedvig Nordeng, University of Oslo
12.45-13.30	LUNCH	

Keynote presentations <i>Moderator: Vera Ehrenstein</i>		
13.30-14.15	Methods: Guidelines for causal inference from pragmatic randomized trials require analytic methods from observational studies	Eleanor Murray, Boston University
14.15-14.45	Methods: Real-world evidence: Studies addressing the complexities of clinical practice or wannabe RCTs - Is it time to rethink the RCT paradigm for observational studies?	Morten Andersen Copenhagen University
Oral presentations (8-minute presentation + 2 minutes' Q&A) <i>Moderators: Maja Hellfritsch Poulsen & Kasper Kristensen</i>		
14.45-15.30	<ul style="list-style-type: none"> • Trial eligibility and treatment outcomes of cancer medicines in a real-world population: an example from Scotland 	Tanja Mueller (UK)
	<ul style="list-style-type: none"> • Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for romiplostim 	Christian Christiansen (DK)
	<ul style="list-style-type: none"> • Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: a nationwide pharmacoepidemiological study 	Lars Kjerpeseth (NO)
	<ul style="list-style-type: none"> • Estimating time on treatment using waiting-time distribution (WTD) and fixed daily dose assumption among initiators of warfarin with non-valvular atrial fibrillation in Denmark, Norway and Sweden 	Morten Madsen (DK)
15.30-16.00	BREAK AND NETWORKING	
Pharmacoepi SLAM - session 1 (3-minute talks) <i>Moderator: Anton Pottegård</i>		
16.00-16.40	<ul style="list-style-type: none"> • Risk of infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab 	Ingvild Odsbu (SE)
	<ul style="list-style-type: none"> • Statin therapy and development of neuropathy in diabetes: A nationwide cohort study 	Frederik Pagh Kristensen (DK)
	<ul style="list-style-type: none"> • Fatal loperamide intoxications in Sweden, 2011 – 2017 	Sara Gustavsson (SE)
	<ul style="list-style-type: none"> • High inappropriate use of prescription opioids in patients with incident knee or hip osteoarthritis 	Jonas Thorlund (DK)
	<ul style="list-style-type: none"> • Use of psychotropic drugs and other tic suppressing medications in children and adolescents with a tic disorder in Denmark 	Lotte Rasmussen (DK)
	<ul style="list-style-type: none"> • The use of medicines that should be avoided among older persons is decreasing in Finland 	Hanna Mari Jauhonen (FI)

	<ul style="list-style-type: none"> • Metformin for treatment of gestational diabetes and risk of delivery by caesarean section • Prenatal exposure to NSAIDs and risk of ADHD diagnosis and symptoms: a follow-up study in the Norwegian Mother, Father and Child Cohort Study 	<p>Carolyn Cesta (SE)</p> <p>Sarah Hjorth Andersen (NO)</p>
<p>Pharmacoepi SLAM - session 2 (3-minute talks) <i>Moderator: Reimar W. Thomsen</i></p>		
16.50-17.30	<ul style="list-style-type: none"> • Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study 	Maurizio Sessa (DK)
	<ul style="list-style-type: none"> • GP attendance in proximity to HPV vaccination: a case-cohort study on experiencing suspected adverse events 	Tina Lützen (DK)
	<ul style="list-style-type: none"> • The Danish National Multiple Myeloma Registry (DMMR): A comprehensive clinical database 	Tina Bech Olesen (DK)
	<ul style="list-style-type: none"> • The utilization of first and second-generation antipsychotic drugs in Denmark from 1999 to 2017: A study using population-based data 	Reeha Sharon (DK)
	<ul style="list-style-type: none"> • Examination of pediatric prescriptions for diabetes mellitus subgroups in primary care 	Volkan Aydin (TR)
	<ul style="list-style-type: none"> • The role of cardiovascular, antilipemic and antidiabetic drugs in risk of death in elderly users of antipsychotic medications: pharmacoepidemiologic study 	Pawel Zagozdzon (PL)
	<ul style="list-style-type: none"> • A dose-dependent increase in mortality in multimorbid and non-multimorbid patients prescribed hypnotics/anxiolytics. A longitudinal cohort study in primary care 	Larus Gudmundsson (IS)
	<ul style="list-style-type: none"> • Examination of generic drug prescribing in primary health care institutions in Turkey 	Dilara Bayram (TR)
17.30-18.00	FREE TIME / Slam winner determination	
18.00	Bus departing for central Aarhus / hotels	
<p>14 November Socializing with colleagues</p>		
19.30-23.00	CONFERENCE DINNER	Restaurant Malt

15 November	Transport	
-------------	------------------	--

08.00	Bus departing for Moesgaard Museum	Pick-up at Scandic City and Scandic The Mayor hotels
-------	------------------------------------	--

15 November	12th NorPEN meeting - Moesgaard Museum Auditorium	
-------------	---	--

8.30-9.00	COFFEE (bus will arrive 8.30)	
-----------	-------------------------------	--

Hot topics: Getting exposed <i>Moderators: Anne Broe & Deirdre Cronin-Fenton</i>		
--	--	--

9.00-9.30	On-treatment – implications for ITT-like and per-protocol like incarnations for interpreting safety and effectiveness data in observational studies	Pål Hasvold, AstraZeneca
-----------	---	--------------------------

9.30-10.00	Methods to estimate treatment duration: why we need dedicated statistical methods and how the Waiting Time Distribution provides new opportunities	Henrik Støvring, Aarhus University
------------	--	------------------------------------

10.00-10.30	The potential of restricting study populations in epidemiological studies of treatment effects	Lars Pedersen, Aarhus University
-------------	--	----------------------------------

10.30-10.50	BREAK/NETWORKING	
-------------	------------------	--

Oral presentations (8-minute presentation + 2 minutes' Q&A) <i>Moderators: Uffe Heide-Jørgensen & Kristina Laugesen</i>		
---	--	--

10.50-12.00	• Are unexplained adverse health events following HPV vaccination associated with infectious mononucleosis? A Danish nationwide matched case-control study	Lene Wulff Krogsgaard (DK)
-------------	--	----------------------------

	• The role of socioeconomic factors on discontinuation of insulin during pregnancy - methodological challenges from a Swedish register based study	Laura Pazzagli (SE)
--	--	---------------------

	• The effect of prenatal exposure to benzodiazepines and z-hypnotics on birth weight and other perinatal outcomes	Anders Huitfeldt (NO)
--	---	-----------------------

	• Safety of modafinil in pregnancy	Anne Broe (DK)
--	------------------------------------	----------------

	• Comparative safety of antiepileptic drugs and risk of major congenital malformations	Jacqueline Cohen (NO)
--	--	-----------------------

	• The One Percent	Lars Christian Lund (DK)
--	-------------------	--------------------------

12.00-12.45	LUNCH	
-------------	-------	--

Data round: Emerging Nordic data sources <i>Moderator: Christian Fynbo Christiansen</i>		
12.45-13.05	The primary care database in Finland – content and use	Jari Haukka University of Tampere
13.05-13.25	The Norwegian Registry for Primary Health Care	Inger Johanne Bakken, Norwegian Directorate of Health, Trondheim
13.25-13.45	The hospital medications database at Copenhagen University	Espen Jimenez-Solem, Copenhagen University
13.45-14.05	The laboratory information system databases in Denmark	Kasper Adelborg, Aarhus University
Closing remarks NorPEN: Quo vadis <i>Moderators: Mette Nørgaard & Vera Ehrenstein</i>		
14.05-14.25	Pharmacoepidemiology: Quo vadis I	Helle Kieler, Karolinska Institutet
14.25-14.45	Pharmacoepidemiology: Quo vadis II	Jesper Hallas, University of Southern Denmark
14.45-15.00	Closing remarks from the organizers New NorPEN Executive Committee members present themselves Announcement of NorPEN 2020 host Adjournment	
15.00	COFFEE TO GO - OR TO STAY	

Locations:

William Scharff Auditorium, Aarhus University campus, the Lake Auditoriums (Danish: Søauditorierne), Bartholins Allé 3, 8000 Aarhus

Moesgaard Museum, Moesgård Allé 15, 8270 Højbjerg

Restaurant Malt, Thorvaldsensgade 33, 8000 Aarhus

Bus drop-off and pick-up: a) Scandic Aarhus City, Østergade 10, 8000 Aarhus
b) Scandic the Mayor, Banegårdspladsen 14, 8000 Aarhus